Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel

Area of Science:

• Pharmacogenomics
• Cardiovascular Medicine
• Neurology

Background:

• CYP2C19 genetic polymorphisms influence clopidogrel response.
• Previous studies linked CYP2C19 variants to cardiovascular event risk in myocardial infarction survivors.
• The impact on stroke recurrence in Chinese populations requires specific investigation.

Purpose of the Study:

• To assess the association between CYP2C19 polymorphisms and stroke recurrence in Chinese patients treated with clopidogrel.
• To evaluate the risk of other vascular events and bleeding complications based on CYP2C19 genotype.
• To determine the clinical significance of CYP2C19 loss-of-function and gain-of-function alleles.

Main Methods:

• A cohort of 625 ischemic stroke patients from the Nanjing Stroke Registry Program was analyzed.
• CYP2C19 variants (*2, *3, and *17) were genotyped using established methods.
• Clinical outcomes, including vascular events and bleeding, were monitored through regular follow-up.

Main Results:

• CYP2C19 loss-of-function (LOF) allele carriers (*2 and *3) showed a significantly higher risk of subsequent vascular events (17.2% vs. 8.1%).
• Adjusted analysis confirmed that CYP2C19 LOF carrier status was an independent predictor of the primary endpoint (HR = 2.31, p = 0.001).
• No significant association was found between CYP2C19 gain-of-function (*17) and clinical events.

Conclusions:

• CYP2C19 LOF alleles are associated with an increased risk of vascular events in Chinese stroke survivors receiving clopidogrel.
• These findings suggest potential benefits of genotype-guided antiplatelet therapy in this patient group.
• Further research may explore tailored clopidogrel dosing or alternative antiplatelet agents based on CYP2C19 genotype.